SABR versus conventional fractionation regimens in NSCLC.

Abstract

The results of the CHISEL trial showing superiority of stereotactic ablative body radiation therapy (SABR) in stage I non-small cell lung cancer (NSCLC) will be welcomed by all radiation oncologists. 1 Ball D Mai GT Vinod S et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol. 2019; 20: 494-503 Google Scholar SABR versus conventional fractionation regimens in NSCLCWe read with interest the publication of the CHISEL trial by David Ball and colleagues,1 which showed the superiority of stereotactic ablative body radiotherapy (SABR) over conventional radiotherapy in time to local failure in stage I (T1–T2 according to TNM 7th edition) non-small-cell lung cancer (NSCLC) and also in terms of overall survival. Full-Text PDF SABR versus conventional fractionation regimens in NSCLC – Authors' replyWe thank Alfredo Addeo and Lucio Buffoni, as well as Nuradh Joseph and Ananya Choudhury, for their interest in, and their comments on, our recently published CHISEL trial.1 In answer to the suggestion that overall survival might have been driven by subsequent treatments, we do not have detailed information about post-relapse treatment since the primary endpoint was local failure. Although a slightly larger proportion of patients with non-squamous histology were randomly assigned to stereotactic ablative body radiotherapy (SABR) than to standard radiotherapy (66% vs 54%), it seems unlikely that there would have been an excess of patients with actionable mutations influencing survival in the SABR group, given that in our population the incidence of such mutations is around 20%. Full-Text PDF Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trialIn patients with inoperable peripherally located stage 1 NSCLC, compared with standard radiotherapy, SABR resulted in superior local control of the primary disease without an increase in major toxicity. The findings of this trial suggest that SABR should be the treatment of choice for this patient group. Full-Text PDF